ZURA

Zura BioC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-22

Current thesis

Runway now appears materially improved through at least end-2028, and two ongoing Phase 2 tibulizumab studies give Zura multiple shots on goal over the next 15 months [#10-K-2026-03-19].

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +22.0.

What can break

Clinical readouts for both lead studies can slip or disappoint, with outsized downside in a single-lead-story biotech.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $5.00 · Bull $9.00 · Bear $2.50

Data freshness

Prices

As of 2026-07-22

Fundamentals

As of 2026-07-22 • Vendor: Data Vendor v1

Scores

As of 2026-07-22 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-22

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $16.00

Why

Momentum84 · Δ7d +22.0

Value41 · Δ7d -0.0

Sentiment44 · Δ7d -11.9

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+22.0

Δ21d

+71.6

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.0

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-11.9

Δ21d

+1.6

Why this grade

Composite grade C. Momentum 84.1 / Value 41.1 / Sentiment 43.9

Fundamentals (TTM)

As of 2026-07-22

Market Cap

$512.99M

Beta

0.21

Shares Out

95M

P/E (TTM) · Derived

-5.1

P/S (TTM)

P/FCF (TTM) · Derived

-6.71

Rev YoY

EPS YoY

+15.1%

Gross Margin

Op Margin

Net Debt

-$109.41M

Current Ratio

19.33

As of 2026-07-22 • Updated nightlySource: Internal modelMethodology